A Multicenter, Open-label Study to Evaluate the Safety and Efficacy of Once Daily Oral Vadadustat for The Treatment of Pediatric Subjects With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-stimulating Agents
Latest Information Update: 03 Oct 2024
At a glance
- Drugs Vadadustat (Primary)
- Indications Anaemia
- Focus Therapeutic Use
- Acronyms CORRECTION
- Sponsors Akebia Therapeutics
- 03 Oct 2024 Status changed from suspended to recruiting.
- 09 Oct 2023 Planned initiation date changed from 1 Jan 2023 to 1 Jan 2025.
- 23 Aug 2022 Planned initiation date changed from 1 May 2022 to 1 Jan 2023.